Ropinirole extends survival by 28 weeks in an ALS clinical trial.

- Posted in Ropinirole extends survival by 28 weeks in an ALS clinical trial. by English by

Some years ago there were great hopes in Pramipexole hydrochloride, a dopamine agonist. A phase III, multicenter, randomized, double-blind, placebo-controlled study of RPPX (EMPOWER) was conducted in ALS patients in the US, Canada, Australia, and Europe; however, regrettably, the results were clinically insignificant.

In 2018 Japanese scientists used induced pluripotent stem cell (iPSC) technology to generate stem and differentiated cells retaining the patients' full genetic information. They thus established a large number of in vitro cellular models of SALS. These models showed phenotypic differences in their pattern of neuronal degeneration, types of abnormal protein aggregates, cell death mechanisms, and onset and progression of these phenotypes in vitro among cases.

The researchers therefore developed a system for case clustering capable of subdividing these heterogeneous SALS models by their in vitro characteristics. They further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole, a drug similar to Pramipexole, as a potential therapeutic candidate.

As a result, ropinirole hydrochloride was eventually selected. Therefore, the scientists wanted to explore the safety, tolerability and efficacy of ropinirole hydrochloride as an ALS treatment in this clinical trial.

Patient recruitment began in December 2018 and the scientists published their results on MedArXiv. Twenty one participants with Amyotrophic Lateral Sclerosis FRS-R scores greater than 2 points were randomly assigned using dynamic allocation to receive ropinirole or placebo for 24 weeks in the double-blind period.

enter image description here

Upon completion, participants could choose to participate in the following 24-week open-label active extension period. The primary outcomes were safety and tolerability. The secondary outcomes for the feasibility trial objective were the change in the ALS FRS-R) score, composite functional endpoint, combined assessment of function and survival, event-free survival, and time to [≤]50% forced vital capacity (blinded outcome assessment).

The participants were randomized into two groups (ropinirole group; n=14) and received ropinirole (n=13) or placebo (n=7) and the data of all participants were analysed using mixed-effects models for repeated measures together.

The incidence of gastrointestinal disorders (mainly, temporary mild nausea and diarrhoea) was high at 77% in the ropinirole group versus 14% in the placebo group). This is common in this type of clinical trial yet it is a major problem to keep long term adherence to the treatment.

Regarding the feasibility of verifying efficacy, there were no significant differences in the ALS FRS-R score and combined assessment of function and survival scores during the double-blind period for 6 months, while the participants in the ropinirole group had lived an additional 28 weeks without disease progression events compared with the placebo group at 12 months. It seems the effect of ropinorole became obvious only after 24 weeks. enter image description here

Ropinirole is thus found (by the authors) safe and tolerable for patients with ALS and this trial indicates feasibility for a subsequent large-scale trial.

Read the original article on medRxiv

Contact the author

Advertisement


This book retraces the main achievements of ALS research over the last 30 years, presents the drugs under clinical trial, as well as ongoing research on future treatments likely to be able stop the disease in a few years and to provide a complete cure in a decade or two.

In Silico Computer Models for Deep Brain Stimulation

- Posted in In Silico Computer Models for Deep Brain Stimulation by English by

Deep brain stimulation (DBS) is an established therapy for patients with Parkinson's disease. enter image description here In silico computer models for DBS allow to pre-select a set of potentially optimal stimulation parameters. If efficacious, they could further carry insight into the mechanism of action of DBS and foster the development of more efficient stimulation approaches. In recent years, the focus has shifted towards DBS-induced firing in myelinated axons, deemed particularly relevant for the external modulation of neural activity.

The scientists in this new medRxiv publication, use the concept of pathway activation modeling, which incorporates advanced volume conductor models and anatomically authentic fiber trajectories to estimate DBS-induced action potential initiation in anatomically plausible pathways that traverse in close proximity to targeted nuclei.

Then the scientists applied the method on a retrospective dataset with the aim of providing a model-based prediction of clinical improvement following DBS (as measured by the motor part of the Unified Parkinsons Disease Rating Scale).

Based on differences in outcome and activation rates for two DBS protocols in a training cohort, the authors computed a theoretical 100% improvement profile and enhanced it by analyzing the importance of profile matching for individual pathways.

Finally, the authors validated the performance of authors' profile-based predictive model in a test cohort.

As a result, the authors demonstrated the clinical utility of pathway activation modeling in the context of motor symptom alleviation in Parkinsons patients treated with DBS.

Read the original article on medRxiv


Please, help us continue to provide valuable information: